METTL3 and neoplasm: In the TIME, depletion of METTL3, or METTL14 depletion within CRC tumors, increases cytotoxic tumor-infiltrating CD8+ T cells and secretion of cytokines such as IFN-γ, CXCL9 and CXCL10, hence sensitizing tumors to PD-1 antibody treatment.